CLINICAL TRIALS PROFILE FOR RAMELTEON
✉ Email this page to a colleague
505(b)(2) Clinical Trials for RAMELTEON
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT02840591 ↗ | Ramelteon and Citicoline for Delirium | Withdrawn | University of Texas Southwestern Medical Center | Phase 4 | 2016-07-01 | Primary aim of this study is to assess the feasibility of conducting clinical research for delirium (confusion due to medical problems) at Clements University Hospital in Dallas, Texas. A secondary aim is to assess whether an FDA-approved sleeping aid called Ramelteon or an over-the-counter supplement called Citicoline are safe and beneficial in delirium. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for RAMELTEON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00237497 ↗ | Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia | Completed | Takeda | Phase 3 | 2005-07-01 | The purpose of the study is to evaluate the safety and efficacy of Ramelteon, once daily (QD), compared to placebo with Zopiclone in adults with chronic insomnia |
| NCT00247390 ↗ | Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia. | Completed | Takeda | Phase 3 | 2005-07-01 | The purpose of this study to determine the long-term efficacy and safety of ramelteon, once daily (QD). |
| NCT00316992 ↗ | Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease | Completed | Takeda | Phase 4 | 2006-04-01 | The purpose of this study is to determine if ramelteon has respiratory depressant effects in subjects with moderate to severe chronic obstructive pulmonary disease. |
| NCT00319215 ↗ | Effects of Ramelteon on Driving Ability | Completed | Takeda | Phase 1 | 2006-03-01 | The primary purpose of this study is to investigate the effects of bedtime administration of a single dose of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on next-morning on-road driving performance. In addition, the drugs' effects on balance are evaluated during the night, and the next morning residual effects on memory and psychomotor performance. |
| NCT00319215 ↗ | Effects of Ramelteon on Driving Ability | Completed | Utrecht Institute for Pharmaceutical Sciences | Phase 1 | 2006-03-01 | The primary purpose of this study is to investigate the effects of bedtime administration of a single dose of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on next-morning on-road driving performance. In addition, the drugs' effects on balance are evaluated during the night, and the next morning residual effects on memory and psychomotor performance. |
| NCT00325728 ↗ | Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease | Completed | Takeda | Phase 2 | 2006-03-21 | The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RAMELTEON
Condition Name
Clinical Trial Locations for RAMELTEON
Trials by Country
Clinical Trial Progress for RAMELTEON
Clinical Trial Phase
Clinical Trial Sponsors for RAMELTEON
Sponsor Name
